Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis

Data ReadoutnegativePelacarsenNegative

AI Analysis

Summary

Novartis' pelacarsen has failed, potentially reshaping the competitive landscape for Lp(a) reduction therapies and benefiting CRISPR and Ionis' programs in this space.

Outcome Details

Pelacarsen failure

Importance:6/10

Sentiment:

-0.70

Lp(a)cardiovasculardrug developmentcompetitive landscapetherapeutic failure

Related Companies

$NVS

Read the original article

Published by yahoo_finance on September 24, 2026 4:42 PM

Read Original